Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, March 13th.
According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
Several other analysts also recently commented on AMPH. BidaskClub downgraded Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 9th. Piper Jaffray reiterated a “buy” rating and set a $26.00 target price on shares of Amphastar Pharmaceuticals in a research report on Tuesday, January 30th. Needham & Company LLC upped their price target on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, December 1st. Finally, BMO Capital Markets restated a “market perform” rating and issued a $19.00 price target (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, March 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $21.33.
NASDAQ:AMPH opened at $19.01 on Tuesday. Amphastar Pharmaceuticals has a 52 week low of $13.15 and a 52 week high of $20.45. The company has a current ratio of 2.79, a quick ratio of 1.85 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $881.59, a price-to-earnings ratio of 50.03, a price-to-earnings-growth ratio of 1.35 and a beta of 1.42.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, March 12th. The company reported $0.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.03. The business had revenue of $60.40 million during the quarter, compared to analysts’ expectations of $60.62 million. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The company’s revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.01 earnings per share. research analysts predict that Amphastar Pharmaceuticals will post 0.63 EPS for the current fiscal year.
In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 19,801 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $20.10, for a total value of $398,000.10. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jason B. Shandell sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 20th. The stock was sold at an average price of $19.43, for a total transaction of $388,600.00. Following the completion of the transaction, the insider now directly owns 251,372 shares in the company, valued at approximately $4,884,157.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 84,387 shares of company stock valued at $1,659,763. 11.10% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the stock. GSA Capital Partners LLP acquired a new position in Amphastar Pharmaceuticals in the third quarter worth approximately $400,000. BNP Paribas Arbitrage SA grew its position in Amphastar Pharmaceuticals by 70.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 17,946 shares of the company’s stock worth $321,000 after purchasing an additional 7,401 shares in the last quarter. Prudential Financial Inc. grew its position in Amphastar Pharmaceuticals by 8.3% during the 3rd quarter. Prudential Financial Inc. now owns 63,580 shares of the company’s stock worth $1,136,000 after purchasing an additional 4,850 shares in the last quarter. Fisher Asset Management LLC grew its position in Amphastar Pharmaceuticals by 8.1% during the 4th quarter. Fisher Asset Management LLC now owns 229,277 shares of the company’s stock worth $4,411,000 after purchasing an additional 17,094 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Amphastar Pharmaceuticals by 17.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock worth $27,844,000 after purchasing an additional 226,271 shares in the last quarter. 44.46% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Amphastar Pharmaceuticals (NASDAQ:AMPH) Downgraded to Hold at Zacks Investment Research” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/amphastar-pharmaceuticals-amph-stock-rating-lowered-by-zacks-investment-research.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.